HUE061607T2 - Imidazopiridin vegyületek mint PAD inhibitorok - Google Patents

Imidazopiridin vegyületek mint PAD inhibitorok

Info

Publication number
HUE061607T2
HUE061607T2 HUE18796135A HUE18796135A HUE061607T2 HU E061607 T2 HUE061607 T2 HU E061607T2 HU E18796135 A HUE18796135 A HU E18796135A HU E18796135 A HUE18796135 A HU E18796135A HU E061607 T2 HUE061607 T2 HU E061607T2
Authority
HU
Hungary
Prior art keywords
imidazo
pyridine compounds
pad inhibitors
inhibitors
pad
Prior art date
Application number
HUE18796135A
Other languages
English (en)
Inventor
Gurulingappa Hallur
Athisayamani Jeyaraj Duraiswamy
Buchi Reddy Purra
N V S K Rao
Sridharan Rajagopal
Rajendra Kristam
Original Assignee
Jubilant Epipad LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jubilant Epipad LLC filed Critical Jubilant Epipad LLC
Publication of HUE061607T2 publication Critical patent/HUE061607T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HUE18796135A 2017-10-18 2018-10-16 Imidazopiridin vegyületek mint PAD inhibitorok HUE061607T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201741037110 2017-10-18

Publications (1)

Publication Number Publication Date
HUE061607T2 true HUE061607T2 (hu) 2023-07-28

Family

ID=64051641

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18796135A HUE061607T2 (hu) 2017-10-18 2018-10-16 Imidazopiridin vegyületek mint PAD inhibitorok

Country Status (20)

Country Link
US (1) US11426412B2 (hu)
EP (1) EP3697785B1 (hu)
JP (1) JP7307723B2 (hu)
KR (1) KR20200071752A (hu)
CN (1) CN111225915B (hu)
AU (1) AU2018352142B2 (hu)
BR (1) BR112020007607A2 (hu)
CA (1) CA3076476A1 (hu)
DK (1) DK3697785T3 (hu)
ES (1) ES2941512T3 (hu)
FI (1) FI3697785T3 (hu)
HU (1) HUE061607T2 (hu)
IL (1) IL272667B (hu)
MX (1) MX2020003341A (hu)
PL (1) PL3697785T3 (hu)
PT (1) PT3697785T (hu)
RS (1) RS64104B1 (hu)
SG (1) SG11202003463XA (hu)
WO (1) WO2019077631A1 (hu)
ZA (1) ZA202002770B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
JP2021534108A (ja) 2018-08-08 2021-12-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ｐａｄ酵素のインドールおよびアザインドール阻害剤
CN112566916B (zh) 2018-08-08 2023-10-20 百时美施贵宝公司 作为pad4抑制剂的经取代的噻吩并吡咯
JP7451419B2 (ja) 2018-10-26 2024-03-18 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
EP3941587A1 (en) 2019-03-19 2022-01-26 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
TW202115083A (zh) * 2019-09-27 2021-04-16 大陸商南京藥捷安康生物科技有限公司 肽醯精胺酸脫亞胺酶抑制劑及其用途
IL292438A (en) 2019-10-28 2022-06-01 Merck Sharp & Dohme Small molecules that inhibit the g12c mutant of kras
WO2021084765A1 (en) * 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd 4-aminobut-2-enamide derivatives and salts thereof
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CR20220550A (es) * 2020-04-30 2022-12-15 Gilead Sciences Inc Inhibidores macrocíclicos de las peptidilarginina deiminasas
WO2021242581A1 (en) 2020-05-29 2021-12-02 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic heterocyclic compounds
IL300502A (en) * 2020-08-12 2023-04-01 Jubilant Epipad LLC Method and compound for use in the treatment and/or prevention of netosis
US11878965B2 (en) 2020-12-22 2024-01-23 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
US20220227787A1 (en) * 2020-12-22 2022-07-21 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
EP4306522A1 (en) * 2021-03-11 2024-01-17 Zhejiang University Fused ring heterocyclic compound and application thereof, and pharmaceutical composition containing same and application thereof
US20240246968A1 (en) * 2021-04-27 2024-07-25 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12c mutant
US11999742B2 (en) 2021-11-01 2024-06-04 Boehringer Ingelheim Vetmedica Gmbh Substituted pyrrolo[1,2-b]pyridazines as anthelmintics

Family Cites Families (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1230663A (hu) 1968-12-10 1971-05-05
GB1356789A (en) 1970-08-06 1974-06-12 Prodotti Antibiotici Spa Derivatives of theophylline
DE2050657C3 (de) 1970-10-15 1974-06-20 Basf Ag, 6700 Ludwigshafen Azofarbstoffe, Verfahren zu ihrer Herstellung und deren Verwendung
US3970753A (en) 1973-06-12 1976-07-20 Smith Kline & French Laboratories Limited Imidazo[1,2-a]pyridines
DE2361390A1 (de) 1973-12-10 1975-06-19 Merck Patent Gmbh Isochinolinderivate und verfahren zu ihrer herstellung
DE2832677A1 (de) 1978-07-26 1980-02-07 Bayer Ag Hydroxypropyl-imidazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4246274A (en) 1978-05-10 1981-01-20 Bayer Aktiengesellschaft Antimycotic hydroxypropyl-imidazoles
DE3210570A1 (de) 1982-03-23 1983-10-06 Hoechst Ag 3-azolyl-1,2-diaryl-1-halogen-1-propene, ihre herstellung, ihre verwendung als pflanzenschutzmittel und diese verbindungen enthaltende praeparate
DE3473442D1 (de) 1983-01-21 1988-09-22 Alkaloida Vegyeszeti Gyar New alkyl diamine derivatives
EP0639582B1 (en) 1985-03-15 1998-09-16 Antivirals Inc. Polynucleotide assay reagent and method
DE3628545A1 (de) 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
JPH07100688B2 (ja) 1986-02-12 1995-11-01 大日本製薬株式会社 環状アミン誘導体
JPH07121911B2 (ja) 1986-03-26 1995-12-25 クミアイ化学工業株式会社 ４（１ｈ）−ピリジノン誘導体および農園芸用殺菌剤
DE3631013A1 (de) 1986-09-12 1988-03-24 Thomae Gmbh Dr K Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3879024T2 (de) 1987-07-31 1993-10-07 Takeda Chemical Industries Ltd Pyridinium-Derivate, ihre Herstellung und Verwendung.
US5179125A (en) 1987-12-03 1993-01-12 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
US5210266A (en) 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
GB8820231D0 (en) * 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
FR2638747B1 (fr) 1988-11-08 1993-12-24 Synthelabo Derives de phenyloxypropanolamines, leur preparation et leur application en therapeutique
DE3901723A1 (de) 1989-01-21 1990-07-26 Bayer Ag Azolyl-derivate
JP2769711B2 (ja) 1989-02-17 1998-06-25 昭和電工株式会社 オレフィン重合用触媒成分の製造方法及びオレフィンの重合方法
EP0481005A1 (de) 1989-07-04 1992-04-22 KUMPF, Ursula Verfahren und einrichtung zum einziehen von insbesondere lichtwellenleiterkabeln in schutzrohre
US5229516A (en) 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5420289A (en) 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
EP0471236B1 (en) 1990-07-30 1995-03-15 Takeda Chemical Industries, Ltd. Imidazopyridine derivatives and their use
ATE141909T1 (de) 1991-07-03 1996-09-15 Shionogi & Co Phospholipase a2 inhibitor
FI924053A (fi) 1991-09-14 1993-03-15 Hoechst Ag Substituerade aminopropaner, foerfarande foer deras framstaellning och deras anvaendning
CA2079374C (en) 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5273980A (en) 1991-09-30 1993-12-28 Merck Frosst Canada Inc. Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5330989A (en) 1991-10-24 1994-07-19 American Home Products Corporation Heterocycles substituted with biphenyl-3-cyclobutene-1,2-dione derivatives
WO1993012094A1 (de) 1991-12-10 1993-06-24 Hoechst Schering Agrevo Gmbh Pyrimidinyl- oder triazinyl-oxy-(oder -thio)-aldehydderivate, und verwendung als herbizide oder pflanzenwachstumsregulatoren
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
DE4227522A1 (de) 1992-08-20 1994-02-24 Bayer Ag Lichtpolarisierende Folien und neue dichroitische Farbstoffe hierfür
JP3298954B2 (ja) 1992-12-16 2002-07-08 三共株式会社 新規ｎ，ｎ’−ジベンゾイルヒドラジン誘導体及び殺虫組成物
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE69411900T2 (de) 1993-03-29 1998-12-10 Zeneca Ltd., London Heterozyklische derivate als plätchenaggregationsinhibitoren
IL109220A0 (en) 1993-04-05 1994-07-31 Synaptic Pharma Corp Dihydropyridines and new uses thereof
EP0700389A1 (en) 1993-05-27 1996-03-13 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
FR2706895A1 (en) 1993-06-22 1994-12-30 Synthelabo Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics
JPH07179402A (ja) 1993-10-20 1995-07-18 Ishihara Sangyo Kaisha Ltd 置換ベンゼン誘導体、その製造方法及びそれを含有する有害生物防除剤
US5461154A (en) 1994-02-02 1995-10-24 Eli Lilly And Company Intermediate and process for making
TW281667B (hu) 1994-02-03 1996-07-21 Synthelabo
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
JPH07304770A (ja) 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピノン誘導体
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
AU4368996A (en) 1994-11-23 1996-06-17 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US5541033A (en) 1995-02-01 1996-07-30 Ocg Microelectronic Materials, Inc. Selected o-quinonediazide sulfonic acid esters of phenolic compounds and their use in radiation-sensitive compositions
US5554621A (en) 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
US20030018025A1 (en) 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
WO1997009066A1 (fr) 1995-09-08 1997-03-13 Kanebo, Ltd. INHIBITEUR DE SOLUBILISATION DE LIGAND Fas
IL125033A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
EP0915888A1 (en) 1996-04-24 1999-05-19 Takeda Chemical Industries, Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
EP1473330B1 (en) 1996-07-17 2007-02-14 Fuji Photo Film Co., Ltd. Process for the synthesis of oxonol compound
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
HN1997000027A (es) 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
HUP9700392A1 (hu) 1997-02-10 1999-09-28 ICN Magyarország Részvénytársaság Egy vagy két hatóanyagot tartalmazó kardioprotektív hatású gyógyszerkészítmények
US6048877A (en) 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents
ATE390404T1 (de) 1997-02-27 2008-04-15 Takeda Pharmaceutical Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
DE19717371A1 (de) 1997-04-24 1998-10-29 Basf Ag Propargyl-terminierte, nematische oder cholesterische Polymere
IL134193A0 (en) 1997-07-31 2001-04-30 Hoffmann La Roche O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents
JPH11119379A (ja) 1997-10-08 1999-04-30 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料および画像形成方法
WO1999032447A2 (en) 1997-12-11 1999-07-01 American Home Products Corporation 2,4,6-trisubstituted pyridines with estrogenic activity and methods for the solid phase synthesis thereof
TW555757B (en) 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
DE19834751A1 (de) 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1123918B1 (en) 1998-10-20 2005-03-09 Takeda Pharmaceutical Company Limited Aromatic amine derivatives, process for the preparation thereof and agents containing the same
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
US6357758B1 (en) 1999-06-30 2002-03-19 Federal-Mogul World Wide, Inc. Metal gasket and method of manufacturing
JP4603679B2 (ja) 1999-12-14 2010-12-22 日本化薬株式会社 害虫防除剤
GB0007108D0 (en) 2000-03-23 2000-05-17 Novartis Ag Organic compounds
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
CN1251671C (zh) 2000-05-19 2006-04-19 武田药品工业株式会社 β分泌酶抑制剂
US7034182B2 (en) 2000-06-30 2006-04-25 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20020094989A1 (en) 2000-10-11 2002-07-18 Hale Jeffrey J. Pyrrolidine modulators of CCR5 chemokine receptor activity
WO2002034716A2 (en) 2000-10-11 2002-05-02 Merck & Co., Inc. Pyrrolidine modulators of ccr5 chemokine receptor activity
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
FR2822153B1 (fr) 2001-03-19 2003-10-31 Servier Lab Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20040016844A (ko) 2001-03-27 2004-02-25 액테리온 파마슈티칼 리미티드 유로텐신 ⅱ 수용체 길항제인1,2,3,4-테트라하이드로이소퀴놀린 유도체
FR2822827B1 (fr) 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
JP4601254B2 (ja) 2001-04-10 2010-12-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｏｒｌ−１受容体介在障害の治療に有用な１，３，８−トリアザスピロ［４．５］デカン−４−オン誘導体
WO2002088089A1 (fr) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
JP4424983B2 (ja) 2001-06-05 2010-03-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド １，４−ジ置換ベンゾ−縮合シクロアルキルウレア化合物
US7192982B2 (en) 2001-06-07 2007-03-20 Ligand Pharmaceuticals, Inc. Modulators of peroxisome proliferator activated receptors
US6887868B2 (en) 2001-09-21 2005-05-03 Pharmacia & Upjohn Company Therapeutic 5-HT ligand compounds
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
SE0103644D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
AU2002353844A1 (en) 2001-11-20 2003-06-10 Eli Lilly And Company Beta 3 adrenergic agonists
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
CA2476681A1 (en) * 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2004011430A1 (ja) 2002-07-25 2004-02-05 Yamanouchi Pharmaceutical Co., Ltd. ナトリウムチャネル阻害剤
EP1388342A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
AU2003271185A1 (en) 2002-10-15 2004-05-04 Takeda Pharmaceutical Company Limited Imidazopyridine derivative, process for producing the same, and use
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
US7381840B2 (en) 2002-12-06 2008-06-03 Xention Limited Tetrahydro-naphthalene derivatives
JP2006511587A (ja) 2002-12-20 2006-04-06 ミジェニックス コーポレイション アデニンヌクレオチドトランスロカーゼ（ａｎｔ）リガンドならびにそれに関連する組成物および方法
WO2004078731A1 (fr) 2003-03-06 2004-09-16 'chemical Diversity Research Institute', Ltd. Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee
US7195849B2 (en) 2003-03-11 2007-03-27 Arch Specialty Chemicals, Inc. Photosensitive resin compositions
JP4226395B2 (ja) 2003-06-16 2009-02-18 アルパイン株式会社 音声補正装置
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US20050159334A1 (en) 2004-01-16 2005-07-21 Gluck Oscar S. Method for treating rheumatoid arthritis by inhibiting peptidylarginine deiminase
EP1735319B1 (en) 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
US7419989B2 (en) 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005016547A1 (de) 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
AR054363A1 (es) 2005-05-23 2007-06-20 Astrazeneca Ab Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6
EP1889301B1 (en) 2005-05-25 2016-09-28 Philips Intellectual Property & Standards GmbH Electroluminescence device
AU2006252540B2 (en) 2005-06-02 2011-12-01 Jenrin Discovery MAO-B inhibitors useful for treating obesity
DE602006019595D1 (de) 2005-06-07 2011-02-24 Theravance Inc Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
TWI610684B (zh) 2005-12-22 2018-01-11 海卓勒生物科學公司 用於調節ｔｒｐａ１功能之化合物
WO2007082806A1 (en) * 2006-01-17 2007-07-26 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer’s disease via gaba receptors
JP2009524689A (ja) 2006-01-25 2009-07-02 スミスクライン ビーチャム コーポレーション 化合物
US20070191371A1 (en) 2006-02-14 2007-08-16 Kalypsys, Inc. Heterocyclic modulators of ppar
WO2007106469A2 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
RU2302417C1 (ru) 2006-03-14 2007-07-10 Иващенко Андрей Александрович 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека
CA2540218A1 (en) 2006-03-17 2007-09-17 Hafedh Trigui Asymmetric beams for spectrum efficiency
DE102006015449A1 (de) 2006-03-31 2007-10-04 Eads Deutschland Gmbh Selbstleuchtender Körper und Verfahren zu seiner Herstellung
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008000408A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis Cxcr2 antagonists
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
DE102006039003A1 (de) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
CN101528744A (zh) 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
AU2007323540A1 (en) 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
MY150731A (en) 2006-11-27 2014-02-28 Lundbeck & Co As H Heteroaryl amide derivatives
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
MX2009006627A (es) 2006-12-22 2009-08-12 Novartis Ag Quinazolinas para la inhibicion de pdk1.
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
US8586619B2 (en) 2007-03-12 2013-11-19 Vm Therapeutics Llc Agents of calcium ion channel modulators
CA2682231A1 (en) 2007-03-28 2008-10-09 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2008123582A1 (ja) 2007-04-04 2008-10-16 Kowa Company, Ltd. テトラヒドロイソキノリン化合物
JP2008280344A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物及びそれを含有する有害節足動物防除剤
TW200902533A (en) 2007-05-02 2009-01-16 Boehringer Ingelheim Int Carboxylic acid amides, manufacturing and use thereof as medicaments
US8003692B2 (en) 2007-06-15 2011-08-23 Board Of Regents, The University Of Texas System Methods and compositions to inhibit edema factor and adenylyl cyclase
WO2008156142A1 (ja) 2007-06-20 2008-12-24 Mitsubishi Tanabe Pharma Corporation 新規なマロン酸スルホンアミド誘導体およびその医薬用途
RU2345996C1 (ru) 2007-07-17 2009-02-10 Андрей Александрович Иващенко Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
EA201000201A1 (ru) 2007-08-10 2010-12-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
WO2009048152A2 (en) 2007-10-11 2009-04-16 Sumitomo Chemical Company, Limited Unsaturated imine compound and use thereof for pest control
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
EP2209371B1 (en) 2007-10-19 2017-01-04 SARcode Bioscience Inc. Compositions and methods for treatment of diabetic retinopathy
EP2072050A1 (en) 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Compounds with anti-emetic effect
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
FR2925902B1 (fr) 2008-01-02 2011-01-07 Sanofi Aventis DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
RU2371444C1 (ru) 2008-01-24 2009-10-27 Андрей Александрович Иващенко ФУРО- И ТИЕНО[2,3-b]-ХИНОЛИН-2-КАРБОКСАМИДЫ, СПОСОБ ПОЛУЧЕНИЯ И ПРОТИВОТУБЕРКУЛЕЗНАЯ АКТИВНОСТЬ
ES2494366T3 (es) 2008-02-22 2014-09-15 Otsuka Pharmaceutical Co., Ltd. Compuesto de benzodiacepina y composición farmacéutica
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
WO2009137309A2 (en) 2008-05-01 2009-11-12 Travel Tech Systems, Llc Process and system to determine commercial airline arrivals
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
WO2009140101A2 (en) 2008-05-12 2009-11-19 Boehringer Ingelheim International Gmbh Imidazopyridine compounds useful as mmp-13 inhibitors
JP2009274984A (ja) 2008-05-14 2009-11-26 Sumitomo Chemical Co Ltd 化合物、光学フィルムおよび光学フィルムの製造方法
US20100121052A1 (en) 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
BRPI0920237A2 (pt) 2008-10-21 2015-12-29 Metabolex Inc agonistas do receptor aril gpr120 e suas respectivas utilizações
DE102008060958A1 (de) 2008-12-06 2010-07-08 Saltigo Gmbh Hydroxytetralone
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
US8367700B2 (en) 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
JP5899607B2 (ja) 2009-03-16 2016-04-06 住友化学株式会社 化合物、光学フィルム及び光学フィルムの製造方法
TWI482769B (zh) 2009-03-16 2015-05-01 Sumitomo Chemical Co 化合物、光學膜片及光學膜片之製造方法
WO2010114896A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
WO2010151799A2 (en) 2009-06-26 2010-12-29 University Of Massachusetts Compounds for modulating rna binding proteins and uses therefor
JP5669481B2 (ja) 2009-08-21 2015-02-12 大塚製薬株式会社 医薬組成物
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
US20110177105A1 (en) 2010-01-15 2011-07-21 Roman Lopez Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications
SI3202461T1 (sl) 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012022045A1 (en) 2010-08-20 2012-02-23 Hutchison Medipharma Limited Pyrrolopyrimidine compounds and uses thereof
MX2013001970A (es) 2010-08-20 2013-08-09 Hutchison Medipharma Ltd Compuestos de pirrolopirimidina y usos de los mismos.
WO2012058133A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Isoindolinone pde10 inhibitors
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
EP2726601B1 (en) 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
JP2014198669A (ja) 2011-08-03 2014-10-23 杏林製薬株式会社 ビアリールエステル誘導体、及びそれらを有効成分とする医薬
WO2013025733A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
MX2014007729A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
BR112014015322A2 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos e composições para inibir a interação de bcl2 com parceiros de ligação
BR112014015339A2 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com parceiros de ligação
JP2015503517A (ja) 2011-12-23 2015-02-02 ノバルティス アーゲー Ｂｃｌ２と結合相手の相互作用を阻害するための化合物
CZ2012114A3 (cs) 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
US8859541B2 (en) 2012-02-27 2014-10-14 Boehringer Ingelheim International Gmbh 6-alkynylpyridines
CA2875990A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
EP2669276A1 (en) 2012-05-31 2013-12-04 Université de Strasbourg Ornithine- and lysine-derivatives for the treatment of pain
US9976133B2 (en) 2012-06-20 2018-05-22 The Regents Of The University Of California Synzymes
FR2993564B1 (fr) 2012-07-20 2014-08-22 Metabrain Res Derives d'imidazopyridine utiles dans le traitement du diabete
CA2879341C (en) * 2012-07-26 2019-06-11 Glaxo Group Limited 2- (azaindol-2-yl) benzimidazoles as pad4 inhibitors
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP6196233B2 (ja) 2012-11-15 2017-09-13 高砂香料工業株式会社 アルミニウム触媒
DK2935222T3 (en) 2012-12-21 2019-01-07 Epizyme Inc PRMT5 INHIBITORS AND APPLICATIONS THEREOF
JP2016511744A (ja) 2012-12-21 2016-04-21 エピザイム，インコーポレイティド Ｐｒｍｔ５を阻害する方法
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
EP3039020B1 (en) 2013-08-27 2017-07-19 Bristol-Myers Squibb Company Ido inhibitors
WO2015034820A1 (en) 2013-09-04 2015-03-12 Bristol-Myers Squibb Company Compounds useful as immunomodulators
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015108038A1 (ja) 2014-01-17 2015-07-23 第一三共株式会社 エチレングリコール化合物
US9890146B2 (en) 2014-02-27 2018-02-13 Ono Pharmaceutical Co., Ltd. Compound having selective EP2 agonist activity
US9067898B1 (en) 2014-03-07 2015-06-30 Janssen Pharmaceutica Nv Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
PL3119772T3 (pl) 2014-03-19 2019-11-29 Boehringer Ingelheim Int Heteroarylowe inhibitory SYK
WO2015197028A1 (en) 2014-06-28 2015-12-30 Sunshine Lake Pharma Co., Ltd. Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine
CA2952083C (en) 2014-07-17 2023-01-24 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
WO2016031815A1 (ja) 2014-08-26 2016-03-03 武田薬品工業株式会社 複素環化合物
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US9877957B2 (en) 2014-09-05 2018-01-30 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
CN105461693B (zh) 2014-09-26 2019-10-25 广东东阳光药业有限公司 Crth2拮抗剂化合物及其用途
JP6840666B2 (ja) 2014-10-03 2021-03-10 マヘーシュワリ, ディヴィヤMAHESHWARI, Divya 新規なアントラニル酸誘導体
ES2578377B1 (es) 2014-12-22 2017-05-04 Consejo Superior De Investigaciones Científicas (Csic) Compuestos moduladores del sensor neuronal de calcio dream y sus usos terapéuticos.
EP3298003B1 (en) * 2015-05-21 2023-04-19 GlaxoSmithKline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
CA2994798A1 (en) 2015-07-03 2017-01-12 Anca CATRINA Methods and compounds for the alleviation and/or prevention of bone loss
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
EA035584B1 (ru) 2015-08-12 2020-07-10 Зингента Партисипейшнс Аг Микробиоцидные гетеробициклические производные
WO2017042182A1 (en) 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2017106634A1 (en) 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
CA3009428A1 (en) 2015-12-22 2017-06-29 AbbVie Deutschland GmbH & Co. KG Fused (hetero)cyclic compounds as s1p modulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
SG11201807021UA (en) 2016-02-23 2018-09-27 Padlock Therapeutics Inc Heteroaryl inhibitors of pad4
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
WO2018002848A1 (en) 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
JP6740452B2 (ja) 2016-07-26 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． プロテインチロシンキナーゼの活性を阻害するためのアミノピリミジン系化合物
EP3493804A1 (en) 2016-08-03 2019-06-12 Arising International, Inc. Symmetric or semi-symmetric compounds useful as immunomodulators
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
CN110099900B (zh) 2016-12-27 2022-12-02 山东大学 针对Smoothened突变株的刺猬通路抑制剂
CN107056630B (zh) 2017-01-23 2020-01-17 合肥工业大学 一种茚满类衍生物及其合成方法和在医药上的用途
US12012467B2 (en) 2017-03-28 2024-06-18 Regents Of The University Of Michigan Small molecule DCN1 inhibitors and therapeutic methods using the same
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
CN107163044B (zh) 2017-06-19 2021-04-23 广东药科大学 一类具有蛋白酶修饰活性的萘乙二酮化合物及其衍生物
WO2018234342A1 (en) 2017-06-21 2018-12-27 F. Hoffmann-La Roche Ag ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4
GB201710851D0 (en) 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
PT3697785T (pt) 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
CN118063442A (zh) 2017-10-20 2024-05-24 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
JP7368369B2 (ja) 2017-11-24 2023-10-24 ジュビラント・エピスクライブ・エルエルシー Ｐｒｍｔ５阻害剤としてのヘテロ環式化合物
KR20200101398A (ko) 2017-12-19 2020-08-27 브리스톨-마이어스 스큅 컴퍼니 Tlr 억제제로서 유용한 아미드 치환된 인돌 화합물
CN110117278B (zh) 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
JP6913226B2 (ja) 2018-02-14 2021-08-04 富士フイルム株式会社 重合性液晶組成物、光学異方性膜、光学フィルム、偏光板および画像表示装置
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
JP6956033B2 (ja) 2018-03-14 2021-10-27 日本化薬株式会社 ベンゾアゾール化合物、並びにこれを含んだ顔料組成物
CN108358917B (zh) 2018-04-24 2020-06-19 北京市结核病胸部肿瘤研究所 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
WO2019205147A1 (zh) 2018-04-28 2019-10-31 上海璃道医药科技有限公司 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途
WO2019213234A1 (en) 2018-05-01 2019-11-07 The Trustees Of Columbia University In The City Of New York Triazolopyrimidines, their preparation and use
WO2020028723A1 (en) 2018-08-01 2020-02-06 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
CA3107548A1 (en) 2018-08-06 2020-02-13 Moexa Pharmaceuticals Limited Smad3 inhibitors
CN112654903B (zh) 2018-08-28 2022-09-27 富士胶片株式会社 层叠体及图像显示装置
CN110963997A (zh) 2018-09-28 2020-04-07 四川科伦博泰生物医药股份有限公司 杂环酰胺类化合物、包含其的药物组合物及其制备方法和用途
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
CN110105299B (zh) 2019-01-23 2023-01-03 中山大学 一种含芳醚取代恶唑烷酮羧酸酯类衍生物及其制备方法和应用
WO2020201773A1 (en) 2019-04-05 2020-10-08 Storm Therapeutics Ltd Mettl3 inhibitory compounds
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
JP7420502B2 (ja) 2019-07-24 2024-01-23 住友化学株式会社 重合性液晶混合組成物、位相差板、楕円偏光板および有機ｅｌ表示装置
AR119494A1 (es) 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
WO2021028810A1 (en) 2019-08-09 2021-02-18 Inorbit Therapeutics Ab Sulfinic acid compounds as free fatty acid receptor agonists
CN114521212B (zh) 2019-09-27 2024-06-21 富士胶片株式会社 液晶组合物、光学各向异性层、光学膜、偏振片及图像显示装置
JP7182533B2 (ja) 2019-09-27 2022-12-02 富士フイルム株式会社 液晶組成物、光学異方性層、光学フィルム、偏光板および画像表示装置
JP7246512B2 (ja) 2019-11-15 2023-03-27 三菱電機株式会社 エッジ機器連携システム、エッジ機器連携方法及びプログラム
KR20210059632A (ko) 2019-11-15 2021-05-25 주식회사유한양행 신규의 2,3-다이하이드로-1h-인덴 또는 2,3-다이하이드로벤조퓨란 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
CN111606904B (zh) 2020-04-07 2021-10-15 广州医科大学 氮杂吲哚类化合物及其应用

Also Published As

Publication number Publication date
EP3697785B1 (en) 2022-12-28
ZA202002770B (en) 2021-10-27
JP7307723B2 (ja) 2023-07-12
IL272667B (en) 2022-09-01
RS64104B1 (sr) 2023-04-28
KR20200071752A (ko) 2020-06-19
SG11202003463XA (en) 2020-05-28
DK3697785T3 (da) 2023-04-03
AU2018352142B2 (en) 2022-08-25
CN111225915B (zh) 2023-03-07
AU2018352142A1 (en) 2020-03-05
CA3076476A1 (en) 2019-04-25
MX2020003341A (es) 2020-09-17
ES2941512T3 (es) 2023-05-23
CN111225915A (zh) 2020-06-02
PT3697785T (pt) 2023-04-03
BR112020007607A2 (pt) 2020-09-29
IL272667A (en) 2020-03-31
RU2020114991A (ru) 2021-11-18
US20200237771A1 (en) 2020-07-30
EP3697785A1 (en) 2020-08-26
PL3697785T3 (pl) 2023-08-07
JP2021500330A (ja) 2021-01-07
US11426412B2 (en) 2022-08-30
FI3697785T3 (fi) 2023-04-03
RU2020114991A3 (hu) 2022-03-30
WO2019077631A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
ZA202002770B (en) Imidazo-pyridine compounds as pad inhibitors
IL273428B1 (en) Heterocyclic compounds as pad inhibitors
IL269196A (en) New inhibitors
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
GB201705971D0 (en) Inhibitor compounds
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
GB201513481D0 (en) Inhibitor compounds
GB201505658D0 (en) Inhibitor compounds
ZA201907136B (en) Ip6k inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
IL274821A (en) Substances that inhibit MPGES-1 and their uses
GB201720145D0 (en) Inhibitor compounds
GB201721465D0 (en) Inhibitors
GB201720189D0 (en) Dopamine-B-hydroxylase inhibitors
GB201708510D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds
GB201522453D0 (en) Inhibitor compounds
GB201500644D0 (en) Inhibitor compounds